狄诺塞麦要用一辈子吗？

In 2018, (denosumab) was included in the list of overseas new drugs in urgent clinical need (first batch) and entered the rapid review channel of the National Medical Products Administration. This approval makes denosumab (denosumab) China's first and currently only drug for the treatment of giant cell tumor of bone, bringing patients an innovative treatment option to control disease progression and improve quality of life.

So does denosumab (denosumab) need to be used for a lifetime? Many patients will have this kind of doubt when taking it.

Denosumab (denosumab) can only be given by subcutaneous injection, not by intravenous infusion, intramuscular infusion or intradermal injection. Giant cell tumor of bone: 120 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. Administer calcium and vitamin D appropriately to prevent hypocalcemia. Bone metastases from solid tumors: 120 mg subcutaneously in the upper arm, thigh, or abdomen every 4 weeks. Malignant hypercalcemia: 20 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

Denosumab (denosumab) is indicated for patients with giant cell tumor of bone who have recurrent, unresectable, or in whom planned surgical resection is likely to result in significant functional disability. The latest analysis of the study, presented at the European Society for Medical Oncology (ESMO) Annual Meeting in 2017, showed that among patients who could be surgically resected, 80% improved after receiving neoadjuvant denosumab: 44% underwent surgery with less impact on function, and 37% avoided surgery. In unresectable patients, denosumab (denosumab) resulted in effective long-term disease control, with a 5-year progression-free survival (PFS) rate of 88%. Whether the patient needs to take (denosumab) long-term still needs to be based on the doctor's advice.

Recommended related hot articles: /newsDetail/77841.html